Publication Name	World Journal of Clinical Oncology
Manuscript ID	66892
Country	Argentina

Received	2021-04-08 15:10
Peer-Review Started	2021-04-12 00:37
First Decision by Editorial Office Director	2021-08-18 03:51
Return for Revision	2021-08-18 03:51
Revised	2021-08-31 21:28
Publication Fee Transferred
Second Decision by Editor	2021-12-29 03:10
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2021-12-31 22:29
Articles in Press	2021-12-31 22:29
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-01-17 13:22
Publish the Manuscript Online	2022-01-22 06:17

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Review
Article Title	New approaches for patients with advanced radioiodine-refractory thyroid cancer
Manuscript Source	Invited Manuscript
All Author List	Fabián Pitoia, Fernando Jerkovich, Pierpaolo Trimboli and Anabella Smulever
Funding Agency and Grant Number
Corresponding Author	Fabián Pitoia, MD, PhD, Doctor, Doctor, Division of Endocrinology, Hospital de Clínicas José de San Martin, University of Buenos Aires, Córdoba 2351, Fifth Floor, Buenos Aires 1120, Argentina. fpitoia@intramed.net
Key Words	Advanced differentiated thyroid cancer; Radioactive iodine refractory thyroid cancer; Multikinase inhibitors; Systemic therapy; Target therapy
Core Tip	The incidence of differentiated thyroid carcinoma has increased due to the rising detection of low-risk small carcinomas. Nevertheless, approximately 10% of patients exhibit advanced disease and two-thirds of the latter will be defined as radioactive iodine (RAI) refractory. After detection, 10-year survival rates are less than 10%, therefore the role of systemic and targeted therapy in these patients has become increasingly relevant in recent years. This review article aims to provide a summary of the current therapeutic strategies in iodine-refractory thyroid cancer, including approved target therapies as well as those for off-label use, RAI resensitization agents, and immunotherapy.
Publish Date	2022-01-22 06:17
Citation	Pitoia F, Jerkovich F, Trimboli P, Smulever A. New approaches for patients with advanced radioiodine-refractory thyroid cancer. World J Clin Oncol 2022; 13(1): 9-27
URL	https://www.wjgnet.com/2218-4333/full/v13/i1/9.htm
DOI	https://dx.doi.org/10.5306/wjco.v13.i1.9

Full Article (PDF)	WJCO-13-9.pdf
Full Article (Word)	WJCO-13-9.docx
Manuscript File	66892_Auto_Edited.docx
Answering Reviewers	66892-Answering reviewers.pdf
Audio Core Tip	66892-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	66892-Conflict-of-interest statement.pdf
Copyright License Agreement	66892-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	66892-Language certificate.pdf
Peer-review Report	66892-Peer-review(s).pdf
Scientific Misconduct Check	66892-Bing-Wu YXJ-2.png
Scientific Editor Work List	66892-Scientific editor work list.pdf
CrossCheck Report	66892-CrossCheck report.pdf